

IN THE CLAIMS

Please amend the claims as follows:

Claim 1. (Currently Amended) A crystal of a pharmaceutically acceptable salt a hydrochloride of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl)urea, wherein said hydrochloride is a hydrochloric acid monoadduct and a monohydrate.

Claims 2-12. (Cancelled)

Claim 13. (Currently Amended) The crystal according to claim 1 or 2, wherein said salt is a hydrochloric acid monoadduct and a monohydrate, and

in powder X-ray diffractometry, the crystal has peaks with not less than 10% relative intensity at at least the following diffraction angles (2θ):

Table A-1

Diffraction angle (2θ)

11.47 ± X

22.59 ± X

23.02 ± X

26.27 ± X

26.63 ± X

wherein X is 0 to 0.20.

Claim 14. (Original) The crystal according to claim 13, wherein the relative intensity in said diffraction angles (2θ) is not less than 15%.

Claim 15. (Original) The crystal according to claim 13, wherein the relative intensity in said diffraction angles (2θ) is not less than 20%.

Claim 16. (Original) The crystal according to claim 13, wherein the relative intensity in said diffraction angles (2θ) is not less than 25%.

Claim 17. (Original) The crystal according to claim 13, wherein the relative intensity in said diffraction angles (2θ) is not less than 30%.

Claim 18. (Original) The crystal according to any one of claims 13 to 17, wherein X is 0 to 0.10.

Claim 19. (Currently Amended) The crystal according to claim 1 or 2, wherein ~~said salt is a hydrochloric acid monoadduct and a monohydrate, and~~

in powder X-ray diffractometry, the crystal has peaks with not less than 10% relative intensity at at least the following diffraction angles (2θ):

Table B-1

Diffraction angle (2θ)

$8.76 \pm X$

$11.47 \pm X$

$15.28 \pm X$

$17.16 \pm X$

$17.53 \pm X$

$18.80 \pm X$

$20.02 \pm X$

$22.59 \pm X$

$23.02 \pm X$

$25.32 \pm X$

$25.43 \pm X$

$26.27 \pm X$

$26.63 \pm X$

$27.00 \pm X$

$28.57 \pm X$

wherein X is 0 to 0.20.

Claim 20. (Original) The crystal according to claim 19, wherein the relative intensity in said diffraction angles (2θ) is not less than 15%.

Claim 21. (Original) The crystal according to claim 19, wherein the relative intensity in said diffraction angles (2θ) is not less than 20%.

Claim 22. (Original) The crystal according to any one of claims 19 to 21, wherein X is 0 to 0.10.

Claim 23. (Currently Amended) The crystal according to claim 1-~~or 2~~, wherein ~~said salt is a hydrochloric acid monoadduct and a monohydrate, and~~

in powder X-ray diffractometry, the crystal has the following diffraction angles (2θ) and relative intensities:

Table 1

<u>Diffraction angle (2θ)</u>	<u>Relative intensity</u>
8.76	22
11.47	100
15.28	21
17.16	21
17.53	23
18.80	21
20.02	25
22.59	35
23.02	37
25.32	29
25.43	23
26.27	36
26.63	32
27.00	29
28.57	28

Claims 24-50 (Cancelled).

Claim 51. (Currently Amended) A process for producing ~~form I~~ a crystal of hydrochloride of N-{2-chloro-4-[$(6,7$ -dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-

isoxazolyl)urea, wherein said hydrochloride is a hydrochloric acid monoadduct and a monohydrate, said process comprising the steps of:

adding hydrochloric acid and ethanol to a solution of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl)urea in an aprotic polar solvent; and precipitating crystals from the solution.

Claim 52. (Original) The process according to claim 51, wherein, in addition to hydrochloric acid and ethanol, water is further added.

Claim 53. (Currently Amended) The process according to claim 51 or 52, wherein said aprotic polar solvent is N,N-dimethylformamide or N,N-dimethylacetamide.

Claim 54. (Currently Amended) The process according to any one of claims claim 51 to 53, wherein said hydrochloric acid has a concentration of 10 to 14 N.

Claim 55. (Currently Amended) The process according to any one of claims claim 51 to 54, wherein said crystal is one according to any one of claims 13 to 23 in powder X-ray diffractometry, the crystal has peaks with not less than 10% relative intensity at at least the following diffraction angles (2θ):

Table A-1

Diffraction angle (2θ)

11.47 ± X

22.59 ± X

23.02 ± X

26.27 ± X

26.63 ± X

wherein X is 0 to 0.20.

Claims 56-67 (Cancelled)

Claim 68. (Currently Amended) A method for the therapy of a disease selected from the group consisting of tumors, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and exudation type age-related maculopathy, comprising

the step of administering an effective amount of the crystal according to ~~any one of claims~~
claim 1 to 50 to a mammal patient.

Claim 69. (Currently Amended) A method for the prophylaxis of metastasis or therapy of a solid tumor, comprising the step of administering an effective amount of the crystal according to ~~any one of claims~~
claim 1 to 50 to a mammal patient.

Claim 70. (Original) The method according to claim 68 or 69, wherein said administration is oral administration.

Claim 71. (Currently Amended) A method for inhibiting angiogenesis of a target blood vessel, comprising the step of bringing an effective amount of the crystal according to ~~any one of claims~~
claim 1 to 50 into contact with vascular endothelial cells of said target blood vessel.

Claims 72-73 (Cancelled).

Claim 74. (New) The process according to claim 52, wherein said aprotic polar solvent is N,N-dimethylformamide or N,N-dimethylacetamide.

Claim 75. (New) The process according to claim 52, wherein said hydrochloric acid has a concentration of 10 to 14 N.

Claim 76. (New) The process according to claim 53, wherein said hydrochloric acid has a concentration of 10 to 14 N.

Claim 77. (New) The process according to claim 52, wherein in powder X-ray diffractometry, the crystal has peaks with not less than 10% relative intensity at at least the following diffraction angles (2 θ):

Table A-1

Diffraction angle (2 θ)

11.47 ± X

22.59 ± X

23.02 ± X

26.27 ± X

26.63 ± X

wherein X is 0 to 0.20.

Claim 78. (New) The process according to claim 53, wherein in powder X-ray diffractometry, the crystal has peaks with not less than 10% relative intensity at at least the following diffraction angles (2θ):

Table A-1

Diffraction angle (2θ)

11.47 ± X

22.59 ± X

23.02 ± X

26.27 ± X

26.63 ± X

wherein X is 0 to 0.20.

Claim 79. (New) The process according to claim 54, wherein in powder X-ray diffractometry, the crystal has peaks with not less than 10% relative intensity at at least the following diffraction angles (2θ):

Table A-1

Diffraction angle (2θ)

11.47 ± X

22.59 ± X

23.02 ± X

26.27 ± X

26.63 ± X

wherein X is 0 to 0.20.